StockData
Cullinan Therapeutics, Inc. logo

Cullinan Therapeutics, Inc. (CGEM) stock

CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$9.28−0.22 (-2.37%)

Close on Nov 17, 2026Market cap $596.89MP/E –Yield –

Cullinan Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Cullinan Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$218.81M. For fiscal 2025 it was -$241.65M. The highest annual figure on record is $144.65M in fiscal 2022.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$241.65M–
FY2024Dec 31, 2024-$196.92M–
FY2023Dec 31, 2023-$191.09M-232.1%
FY2022Dec 31, 2022$144.65M–
FY2021Dec 31, 2021-$67.95M–
FY2020Dec 31, 2020-$60.34M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$52.60M–
Q2 FY2026Jun 30, 2026-$57.25M–
Q1 FY2026Mar 31, 2026-$53.70M–
Q4 FY2025Dec 31, 2025-$55.26M–
Q3 FY2025Sep 30, 2025-$55.60M–
Q2 FY2025Jun 30, 2025-$75.80M–
Q1 FY2025Mar 31, 2025-$55.00M–
Q4 FY2024Dec 31, 2024-$55.05M–
Q3 FY2024Sep 30, 2024-$48.86M–
Q2 FY2024Jun 30, 2024-$50.03M–
Q1 FY2024Mar 31, 2024-$42.99M–
Q4 FY2023Dec 31, 2023-$45.49M–
Q3 FY2023Sep 30, 2023-$45.24M–
Q2 FY2023Jun 30, 2023-$37.61M-115.7%
Q1 FY2023Mar 31, 2023-$62.76M–
Q4 FY2022Dec 31, 2022-$32.61M–
Q3 FY2022Sep 30, 2022-$29.77M–
Q2 FY2022Jun 30, 2022$239.68M–
Q1 FY2022Mar 31, 2022-$32.66M-2480.2%
Q4 FY2021Dec 31, 2021-$34.35M–
Q3 FY2021Sep 30, 2021-$18.38M–
Q2 FY2021Jun 30, 2021-$16.60M–
Q1 FY2021Mar 31, 2021$1.37M–
Q4 FY2020Dec 31, 2020-$29.17M–
Q3 FY2020Sep 30, 2020-$11.50M–
Q2 FY2020Jun 30, 2020-$14.12M–
Q1 FY2020Mar 31, 2020-$5.54M–

More Cullinan Therapeutics figures

See a number that looks wrong?